Loading organizations...
Highlight Capital is a private investment firm based in Tokyo, Japan, with operations in Shanghai, Hong Kong, and Boston, focusing on technology innovations within the healthcare, biotech, and consumer sectors across Asia. The firm manages over US$3.8 billion in assets across five closed funds, including the HighLight Capital USD Fund IV, which closed in December 2023. It leverages expertise in chemical, biological, and material sciences to support companies improving manufacturing efficiency and human wellness, particularly in areas like AI, robotics, and advanced biotech. Founder and CEO Steven Wang has noted the entry of China's biotech sector into a "true innovation phase." With 21-50 employees, key leadership also includes Partner and Co-Founder Bruce Xing and Managing Director Shuichi Shimizu. Highlight Capital was founded in 2014 by Steven Wang.
Highlight Capital has 2 tracked investments across 2 companies. The latest tracked deal is $35.0M Seed in Spurious in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 30, 2026 | Spurious | $35.0M Seed | Highlight Capital | Biotrack Capital, Hankang Capital, InnoPinnacle Fund, Lichen Capital, LongRiver Investments |
| Jan 30, 2026 | Yiteng Medical | $14.4M Series A | Highlight Capital | Kunshan GuoChuang Investment, Kunyu Talent Fund |
